Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster advised Immune-Onc Therapeutics, Inc. in a $73 million follow-on to its previous Series B financing. The round was led by Oceanpine Capital with participation from additional new investors, including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.

MoFo Advises Immune-Onc in $73 Million Financing

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster advised Immune-Onc Therapeutics, Inc. in a $73 million follow-on to its previous Series B financing. The round was led by Oceanpine Capital with participation from additional new investors, including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.Based in Palo Alto, California, Immune-Onc is a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints. Proceeds from the financing will allow Immune-Onc to advance its portfolio of blood cancer and solid tumor immunotherapies targeting myeloid checkpoints with a focus on the LILRB family.The MoFo deal team was led by John Campbell, senior counsel in the firm’s Emerging Companies + Venture Capital Group in San Francisco, with assistance from Charles Comey, a partner focused on investment transactions between China and the United States, and associates Jim Ryan and Ophir Gam, all based in Palo Alto.For further information on the company and transaction, see the <a target="_blank" href="https://www.businesswire.com/news/home/20210330005050/en/Immune-Onc-Therapeutics-Announces-73-Million-in-Series-B1-and-B2-Financing-to-Advance-its-Portfolio-of-Novel-Immunotherapies-in-Blood-Cancers-and-Solid-Tumors">press release</a>.

MoFo Advises Immune-Onc in $73 Million Financing

Sign Up

John W. Campbell

Senior Counsel

Charles C. Comey

Jim Ryan

Associate

Ophir Gam

Corporate Finance | Capital Markets

Emerging Companies + Venture Capital